Similarly, ELTD1 protein levels decreased upon treatment with a VEGFR neutralizing antibody.118 Furthermore, in vivo administration of a monoclonal antibody targeting ELTD1 reduced GBM tumor volume and microvessel density compared to an untreated control.114 These studies highlight the potential use of anti-ELTD1 neutralizing antibodies for anti-angiogenic therapy of GBM tumors.114,118,119. The gene discussed is ADGRL4; the disease is glioblastoma.